

## Gerinnungsstörung bei COVID-19

1. Nishimura, H. and M. Yamaya, A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease. *Tohoku J Exp Med*, 2015. 237(1): p. 45-50.
2. Lin, L., et al., Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. *Emerg Microbes Infect*, 2020. 9(1): p. 727-732.
3. Chuansumrit, A. and W. Chaiyaratana, Hemostatic derangement in dengue hemorrhagic fever. *Thromb Res*, 2014. 133(1): p. 10-6.
4. Han, H., et al., Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med*, 2020. 58(7): p. 1116-1120.
5. Iba, T. and J.H. Levy, Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. *Anesthesiology*, 2020. 132(5): p. 1238-1245.
6. Geisbert, T.W., et al., Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. *Lancet*, 2003. 362(9400): p. 1953-8.
7. Tang, N., et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*, 2020. 18(5): p. 1094-1099.
8. Middleton, E.A., et al., Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome. *Blood*, 2020.
9. Wang, J., et al., Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *J Leukoc Biol*, 2020. 108(1): p. 17-41.
10. Iba, T., et al., Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccharide-induced acute lung inflammation in hamsters. *Shock*, 2006. 26(1): p. 95-8.
11. Luo, W., et al., Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). , in *Preprints 2020*. 2020.
12. Wang, D., et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 2020.
13. Chen, H.R., et al., Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. *PLoS Pathog*, 2018. 14(4): p. e1007033.
14. To, K.F. and A.W. Lo, Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). *J Pathol*, 2004. 203(3): p. 740-3.
15. Zhao, X., J.M. Nicholls, and Y.G. Chen, Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. *J Biol Chem*, 2008. 283(6): p. 3272-80.
16. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 2020. 395(10223): p. 497-506.
17. Hanify, J.M., et al., Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis. *J Crit Care*, 2017. 37: p. 206-210.
18. Poissy, J., et al., Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. *Circulation*, 2020. 142(2): p. 184-186.
19. Klok, F.A., et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*, 2020. 191: p. 145-147.
20. Cui, S., et al., Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*, 2020. 18(6): p. 1421-1424.
21. Danzi, G.B., et al., Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J*, 2020. 41(19): p. 1858.
22. Xie, Y., et al., COVID-19 Complicated by Acute Pulmonary Embolism. *Radiology: Cardiothoracic Imaging*, 2020. 2(2): p. e200067.
23. Lippi, G., M. Plebani, and B.M. Henry, Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*, 2020. 506: p. 145-148.
24. Guan, W.J., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, 2020. 382(18): p. 1708-1720.
25. Thachil, J., et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost*, 2020. 18(5): p. 1023-1026.

26. Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 2020. 395(10229): p. 1054-1062.
27. Tang, N., et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*, 2020. 18(4): p. 844-847.
28. Schnittler, H.J. and H. Feldmann, Viral hemorrhagic fever--a vascular disease? *Thromb Haemost*, 2003. 89(6): p. 967-72.
29. Wu, C., et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*, 2020.